Collegium Pharmaceutical: Oversold And Cheap
June 15, 2022
Collegium Pharmaceutical: Oversold And Cheap[Collegium Pharmaceutical, Inc. (COLL)]
Summary
– Shares of pain management drug concern Collegium Pharmaceutical have fallen over 40% as the biotech selloff, negative attitudes towards opiates, and patent cliffs have taken a toll. – The company’s recent purchase of BioDelivery Sciences provides it with complementary suite of assets, an entry into neurology, and $75 million of cost synergies.
Read the source article at seekingalpha.com
2022-06-12 14:35:00